Drug Profile

Research programme: glycan-binding biopharmaceuticals - ProtAffin Biotechnologie

Alternative Names: MCP-1 programme - ProtAffin; Oncology programme - ProtAffin; PA508; SDF-1α programme - ProtAffin

Latest Information Update: 04 Sep 2013

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ProtAffin Biotechnologie
Class Proteins
Mechanism of Action Glycosaminoglycan inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Cancer; Coronary artery restenosis; Diabetic retinopathy; Fibrosis; Multiple sclerosis; Myocardial infarction; Uveitis

Most Recent Events

31 Jul 2013 ProtAffin Biotechnologie has ceased operations
31 Jul 2013 Discontinued - Preclinical for Coronary artery restenosis in Austria (Parenteral)
31 Jul 2013 Discontinued - Preclinical for Multiple sclerosis in Austria (Parenteral)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com